BiotechTube
Genovis AB

Genovis AB

GENO.STPre-clinical
50-100 employeesgenovis.com

Genovis AB leverages its proprietary SmartEnzymes™ technology to provide critical tools for the biopharmaceutical industry, focusing on the analysis and engineering of next-generation biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecifics. The company has established itself as a key supplier to leading pharma and biotech companies globally, supporting the development of complex therapeutics. Its strategy involves expanding its product portfolio for protein characterization and bioprocessing while exploring new applications in cell and gene therapy. As a publicly listed company, Genovis aims to capitalize on the growing demand for advanced analytical solutions in the biologics market.

Market Cap
$116.8M
-19.7% period
Pipeline
—
Patents
7
granted
Publications
20
indexed

GENO.ST · Stock Price

USD 16.464.04 (-19.71%)

Historical price data

AI Company Overview

Genovis AB leverages its proprietary SmartEnzymes™ technology to provide critical tools for the biopharmaceutical industry, focusing on the analysis and engineering of next-generation biologics, including monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecifics. The company has established itself as a key supplier to leading pharma and biotech companies globally, supporting the development of complex therapeutics. Its strategy involves expanding its product portfolio for protein characterization and bioprocessing while exploring new applications in cell and gene therapy. As a publicly listed company, Genovis aims to capitalize on the growing demand for advanced analytical solutions in the biologics market.

Biotech

Technology Platform

Proprietary SmartEnzymes™ platform, consisting of highly specific, recombinant enzymes (like IdeS) for the precise fragmentation, analysis, and engineering of therapeutic antibodies and other proteins.

Funding History

1
IPOUndisclosedJun 5, 2015

Opportunities

Growth is driven by the expanding market for complex biologics like ADCs and bispecific antibodies, which require advanced analytical tools.
Further opportunities exist in expanding into new geographic markets and developing enzyme applications for emerging cell and gene therapy modalities.

Risk Factors

Key risks include dependence on biopharma R&D spending cycles, competition from larger life science tools companies, and the need to continuously innovate and protect intellectual property to maintain its technological edge.

Competitive Landscape

Main competitors include large life science tools conglomerates like Thermo Fisher Scientific and specialized reagent suppliers. Genovis differentiates itself through the superior specificity and speed of its proprietary SmartEnzymes™ and deep application expertise in biopharma protein analysis.